EFFECT OF REPIRINAST ON THE PREVENTION OF PEDIATRIC BRONCHIAL ASTHMA

Abstract

Children with bronchial asthma aged between 1 and 16 years were observed for 2 weeks, and subsequently received repirinast at a daily oral dose of 8mg/kg for 26 weeks.
1. According to the impression of the affected children and the results of the evaluation of overall improvement and usefulness, repirinast was highly useful. The improvement rate increased along with the progress of the study, and the percentage of patients showing mild or better improvement fluctuated around 90% from week 12 of the study.
2. Compared with the observation period, the clinical score was significantly reduced throughout the entire study period (the treatment score was reduced from week 4).
3. 46.5% of the patient received repirinast for 26 weeks. Among them, 12 patients were symptomatically stable, and no increase in the treatment score was observed.
Based on these results, the clinical efficancy of repirinast (Romet^® fine granule for children) was confirmed. However the final number of evaluable patients was considered to be 12, in this study, no use of any concomitant drug was intented, improvement was evaluated during a limited period of 4 weeks, and the dose of repirinast was subsequently reduced.